Patents by Inventor Ronald Vogels
Ronald Vogels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120075027Abstract: A MEMS resonator comprises a resonator body (34), and an anchor (32) which provides a fixed connection between the resonator body (34) and a support body. A resistive heating element (R1,R2) and a feedback control system are used to maintain the resonator body (34) at a constant temperature. A location for thermally coupling the anchor (32) to the resistive heating element (R1,R2) is selected which has a lowest dependency of its temperature on the ambient temperature during the operation of the feedback control.Type: ApplicationFiled: September 7, 2009Publication date: March 29, 2012Applicant: NXP B.V.Inventors: Jozef Thomas Martinus van Beek, Ronald Vogels
-
Patent number: 8114637Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. Provided are means and methods for reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: GrantFiled: July 14, 2010Date of Patent: February 14, 2012Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20110311580Abstract: Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.Type: ApplicationFiled: August 23, 2011Publication date: December 22, 2011Inventors: Ronald Vogels, Maria Grazia Pau, Lennart Holterman, Stefan Kostense, Menzo Jans Emco Havenga, Mieke Caroline Sprangers
-
Patent number: 8076131Abstract: The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.Type: GrantFiled: August 24, 2009Date of Patent: December 13, 2011Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Maria Grazia Pau, Lennart Holterman, Stefan Kostense, Menzo Jans Emco Havenga, Mieke Caroline Sprangers
-
Publication number: 20110281347Abstract: Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: ApplicationFiled: May 31, 2011Publication date: November 17, 2011Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Radosevic
-
Patent number: 8052967Abstract: Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: September 5, 2007Date of Patent: November 8, 2011Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20110256166Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: ApplicationFiled: May 31, 2011Publication date: October 20, 2011Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Radosevic
-
Patent number: 8012467Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: GrantFiled: November 15, 2005Date of Patent: September 6, 2011Assignees: Crucell Holland B.V., Aeras Global TB Vaccine FoundationInventors: Menzo J. E. Havenga, Ronald Vogels, Jerald Sadoff, David Hone, Yasir A. W. Skeiky, Katarina Radosevic
-
Patent number: 7968087Abstract: A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprise a tissue tropism-determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing these gene delivery vehicles are provided.Type: GrantFiled: May 28, 2009Date of Patent: June 28, 2011Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo J. E. Havenga, Abraham Bout
-
Patent number: 7906113Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: GrantFiled: October 25, 2006Date of Patent: March 15, 2011Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Publication number: 20100311172Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. Provided are means and methods for reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: ApplicationFiled: July 14, 2010Publication date: December 9, 2010Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Patent number: 7820440Abstract: The invention relates to methods and means for producing adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: May 7, 2007Date of Patent: October 26, 2010Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Patent number: 7816104Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. The invention provides means and methods reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: GrantFiled: March 20, 2006Date of Patent: October 19, 2010Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Patent number: 7749493Abstract: The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.Type: GrantFiled: August 18, 2005Date of Patent: July 6, 2010Assignee: Crucell Holland B.V.Inventors: Menzo Havenga, Ronald Vogels, Abraham Bout
-
Publication number: 20100034774Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: ApplicationFiled: July 23, 2009Publication date: February 11, 2010Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Angelique A.C. Lemckert, Menzo J.E. Havenga
-
Publication number: 20100015176Abstract: The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.Type: ApplicationFiled: August 24, 2009Publication date: January 21, 2010Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Maria Grazia Pau, Lennart Holterman, Stefan Kostense, Menzo Jans Emco Havenga, Mieke Caroline Sprangers
-
Patent number: 7604960Abstract: Described is a method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein the adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of the first region and the second region is required for adenoviral genome replication and/or adenovirus particle formation, b) propagating the adenoviral vector in a first type of complementing cells that express proteins from the first and from the second region of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, c) infecting a culture of a second type of complementing cells with the recombinant adenovirus particles, wherein the second type of complementing cells express protein from the first region of the adenovirus genome but not protein from the second region of the adenovirus genome,Type: GrantFiled: June 1, 2007Date of Patent: October 20, 2009Assignee: Crucell Holland B.V.Inventors: Guus Hateboer, Menzo J. E. Havenga, Ronald Vogels, Lennart Holterman
-
Publication number: 20090253207Abstract: A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprise a tissue tropism-determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing these gene delivery vehicles are provided.Type: ApplicationFiled: May 28, 2009Publication date: October 8, 2009Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo J. E. Havenga, Abraham Bout
-
Patent number: 7598078Abstract: The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.Type: GrantFiled: April 14, 2005Date of Patent: October 6, 2009Assignee: Crucell Holland B.V.Inventors: Menzo Jans Havenga, Lennart Holterman, Stefan Kostense, Maria Grazia Pau, Mieke C. Sprangers, Ronald Vogels
-
Publication number: 20090123438Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: ApplicationFiled: November 15, 2005Publication date: May 14, 2009Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Radosevic